# RENOIR (NCT02390869)

> Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

No report yet. It can be ordered.

- Drugs tested: lenalidomide plus rituximab
- Indication: relapsed/refractory follicular lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02390869
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Fondazione Italiana Linfomi - ETS
- Conditions: Lymphoma, Follicular
- Interventions: R2-MANT; R-MANT
- Enrollment: 128
- Primary outcome: PFS

## Indexed commentary on RENOIR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 2
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=renoir-nct02390869